Guido Oelkers, CEO of listed biopharma Swedish Orphan Biovitrum (Sobi), is stepping down from his current role to take up another position outside Sobi. He will remain in-post until the end January 2027 at the latest.
Sobi has begun the process of identifying a successor.
Oelkers joined Sobi in 2017.
Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK28bn (US$2.94bn).






